White Pine Capital LLC bought a new position in shares of Solventum Corporation (NYSE:SOLV – Free Report) during the third quarter, Holdings Channel.com reports. The firm bought 24,898 shares of the company’s stock, valued at approximately $2,195,000.
Other institutional investors have also recently made changes to their positions in the company. Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of Solventum in the 2nd quarter worth approximately $150,066,000. Bank of America Corp DE boosted its position in shares of Solventum by 0.6% during the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock valued at $93,561,000 after purchasing an additional 9,083 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Solventum in the second quarter worth $61,460,000. Dimensional Fund Advisors LP grew its stake in Solventum by 44.0% in the first quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock worth $50,576,000 after purchasing an additional 236,659 shares during the period. Finally, KBC Group NV raised its holdings in Solventum by 36.9% in the first quarter. KBC Group NV now owns 632,833 shares of the company’s stock worth $41,324,000 after purchasing an additional 170,416 shares in the last quarter.
Solventum Price Performance
SOLV stock opened at $88.85 on Monday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.72 and a current ratio of 1.03. The firm has a 50 day moving average price of $87.53 and a 200-day moving average price of $78.95. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $94.16. The firm has a market capitalization of $15.08 billion, a price-to-earnings ratio of 99.83, a PEG ratio of 1.27 and a beta of 0.69.
Solventum (NYSE:SOLV – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.11. The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.93 billion. Solventum had a return on equity of 25.03% and a net margin of 1.91%. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.50 EPS. Equities research analysts forecast that Solventum Corporation will post 7.26 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on SOLV. Wells Fargo & Company increased their price objective on Solventum from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, November 6th. KeyCorp boosted their target price on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Mizuho set a $113.00 target price on shares of Solventum in a research report on Thursday, August 6th. Weiss Ratings lowered shares of Solventum from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Monday, November 9th. Finally, UBS Group increased their price target on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.27.
Check Out Our Latest Analysis on SOLV
Solventum Profile
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Featured Articles
- Five stocks we like better than Solventum
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
